Development of Cagrilintide, a Long Acting Amylin Analogue ScienceDirect Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet